How to Get Rapamycin (Sirolimus) in Georgia

Rapamycin Prescribing Is Legal via Telehealth in Georgia

Georgia permits telehealth prescribing of rapamycin (sirolimus) under OCGA § 33-24-56.4, which authorizes physicians and eligible mid-level providers to prescribe non-controlled medications after a synchronous audio-video visit. Sirolimus is not a controlled substance under Georgia or federal scheduling, so it qualifies for telehealth initiation without an in-person encounter.

Any Georgia-licensed MD or DO can write the prescription. Nurse practitioners hold prescriptive authority under a collaborative practice agreement with a physician, per the Georgia Board of Nursing rules [1]. Physician assistants prescribe under a delegation agreement with their supervising physician. In practice, most off-label rapamycin prescriptions for longevity originate from MDs or DOs practicing in anti-aging, functional medicine, or endocrinology.

The telehealth visit itself typically runs 15 to 30 minutes. During this appointment, the prescriber reviews your medical history, confirms that baseline laboratory work is current, evaluates contraindications (active infection, uncontrolled hyperlipidemia, hepatic impairment), and discusses the off-label nature of the prescription. Georgia does not require a separate informed-consent form for off-label prescribing, but most longevity clinicians document signed consent as standard practice.

What Labs You Need Before Starting Sirolimus

Baseline bloodwork is non-negotiable. Every prescriber following evidence-based longevity protocols will require labs drawn within the prior 60 days before writing a rapamycin prescription.

The minimum panel includes a complete blood count (CBC), comprehensive metabolic panel (CMP), fasting lipid panel, fasting glucose, and HbA1c. The CBC screens for thrombocytopenia and leukopenia, both known dose-dependent effects of mTOR inhibition [2]. The lipid panel is especially relevant: in the PEARL trial (N=30, published in Aging Cell 2024), participants receiving low-dose rapamycin showed changes in lipid markers that required monitoring at 6 and 12 months [3]. Your prescriber may also order a fasting insulin level and high-sensitivity CRP to establish a metabolic baseline.

Follow-up labs are typically repeated at 4 to 6 weeks after initiation, then every 3 months for the first year. After 12 months of stable dosing with no laboratory abnormalities, many clinicians extend the monitoring interval to every 6 months. The FDA-approved prescribing information for sirolimus recommends routine monitoring of lipid profiles, renal function, and blood counts for all patients on the drug [4].

Georgia residents can complete labs at any Quest Diagnostics, Labcorp, or hospital-affiliated draw station in the state. Most telehealth longevity clinics provide a lab requisition that you bring to the draw site. Turnaround is 24 to 72 hours for standard panels.

How 503A Compounding Pharmacies Work in Georgia

Georgia licenses 503A compounding pharmacies through the Georgia Board of Pharmacy under OCGA § 26-4-110. These pharmacies compound medications pursuant to a valid patient-specific prescription. They cannot compound in bulk for general distribution (that is the role of 503B outsourcing facilities under federal law), but they can prepare and ship a compounded sirolimus prescription directly to a Georgia patient.

Why compounding? Cost is the primary driver. Brand-name Rapamune (Pfizer) carries a retail cash price exceeding $900 for thirty 1 mg tablets. Generic sirolimus tablets range from $150 to $400 per month depending on dose and pharmacy. A 503A compounding pharmacy can prepare sirolimus capsules at the specific weekly dose your prescriber orders (commonly 5 mg or 6 mg capsules taken once per week) for $60 to $150 per month, depending on the pharmacy and dose.

Georgia-based 503A pharmacies that compound sirolimus typically ship via USPS Priority Mail or FedEx with cold-chain packaging when required. Out-of-state 503A pharmacies can also ship into Georgia, provided they hold a nonresident pharmacy license issued by the Georgia Board of Pharmacy. Confirm this license before placing an order. The Georgia Board maintains a searchable license verification database that patients can check.

Compounded sirolimus is available in oral capsule or solution form. The once-weekly longevity dosing protocol (typically 3 to 6 mg) is most commonly dispensed as capsules. Your prescriber writes the prescription specifying the exact milligram dose, and the compounding pharmacist fills it accordingly.

Georgia Medicaid Does Not Cover Off-Label Longevity Use

Georgia Medicaid covers sirolimus only for its FDA-approved indication: prevention of organ transplant rejection [5]. The off-label longevity application has no Medicaid coverage pathway in Georgia as of 2026. This applies to both fee-for-service Medicaid and Georgia's managed care organizations (Amerigroup, CareSource, Peach State Health Plan).

Commercial insurance plans in Georgia vary. Some cover generic sirolimus with prior authorization when prescribed for an off-label but medically supported indication. The prior authorization process typically requires the prescriber to submit documentation that includes the specific clinical rationale, supporting literature references, baseline lab results, and confirmation that the patient has no contraindications listed on the FDA label.

Dr. Matt Kaeberlein, a prominent researcher in the biology of aging at the University of Washington, has stated: "Rapamycin is the most promising pharmacological intervention for extending healthspan that we have identified in preclinical models, but insurance coverage for longevity use remains a major barrier for patients across the country" [6].

For patients paying out of pocket, the 503A compounding route described above is the most cost-effective option. Some telehealth longevity clinics also negotiate volume pricing with their pharmacy partners, bringing the per-month cost below $100 for standard weekly dosing.

The Prescription Transfer Process in Georgia

Georgia law permits the transfer of prescriptions between pharmacies under Georgia Board of Pharmacy Rule 480-10-.03. If you already hold a valid rapamycin prescription from another state, a Georgia-licensed pharmacy can accept the transfer, provided the originating prescriber holds an active license (in any U.S. state) and the prescription has remaining refills.

The process works like this. You contact the receiving Georgia pharmacy and provide the originating pharmacy's name and phone number. The pharmacist at the receiving pharmacy calls the originating pharmacy to verify and transfer the prescription. For compounded prescriptions, the transfer must go to a compounding pharmacy capable of preparing the same formulation.

One caveat: if the originating prescription was written by a prescriber in a state that restricts telehealth prescribing across state lines, the Georgia pharmacy may require a new prescription from a Georgia-licensed provider. This is the safer and faster route in most cases. A new telehealth consultation with a Georgia-licensed provider typically costs $99 to $250 and eliminates any jurisdictional ambiguity.

Timeline From Consultation to First Dose

Most Georgia patients receive their first rapamycin dose within 5 to 14 days of initial contact with a telehealth provider. Here is the typical sequence.

Days 1 to 2: You schedule a telehealth consultation and receive a lab requisition. Days 2 to 4: You complete the blood draw at a local lab. Days 4 to 6: Lab results return and the prescriber reviews them during a synchronous video visit. Day 6 or 7: The prescriber transmits the prescription electronically to the compounding pharmacy. Days 7 to 14: The pharmacy compounds, packages, and ships the medication.

Delays occur most often at the lab stage. If you already have qualifying labs drawn within 60 days, you can skip the waiting period and move directly to the clinical consultation. Some telehealth platforms in the longevity space offer same-day or next-day video visits, compressing the total timeline to as few as 5 business days.

For patients using a retail pharmacy to fill a generic sirolimus prescription (rather than a compounding pharmacy), the timeline is shorter. Most retail pharmacies in Georgia stock generic sirolimus or can order it within 24 to 48 hours.

Prior Authorization Requirements for Georgia Insurers

When commercial insurance is involved, prior authorization (PA) is almost always required for sirolimus prescribed off-label. The documentation package your prescriber submits typically includes four elements: a letter of medical necessity citing the clinical rationale and supporting literature, the patient's baseline lab results, a list of current medications to demonstrate no contraindicated drug interactions, and confirmation of the patient's informed consent for off-label use.

The Endocrine Society's 2024 position statement on off-label prescribing notes that "physicians should document the evidence basis, expected benefits, and monitoring plan when prescribing medications outside their FDA-approved indications" [7]. Georgia insurers generally follow this standard.

PA turnaround time varies by insurer. Anthem Blue Cross Blue Shield of Georgia and Aetna typically respond within 5 to 10 business days. UnitedHealthcare and Cigna may take up to 15 business days. If denied, Georgia law (OCGA § 33-20A-9) grants patients the right to an expedited external review of adverse benefit determinations, including PA denials.

The denial rate for off-label sirolimus is high. Most longevity patients bypass insurance entirely and pay cash through a compounding pharmacy, which eliminates the PA process and reduces total wait time by 1 to 3 weeks.

Clinical Evidence Supporting Low-Dose Rapamycin for Longevity

The interest in rapamycin for longevity stems from decades of preclinical data showing that mTOR inhibition extends lifespan across multiple species. The National Institute on Aging's Interventions Testing Program (ITP) demonstrated that rapamycin extended median lifespan by 9% in male mice and 14% in female mice when started at 20 months of age (roughly equivalent to age 60 in humans) [8].

Human data is still emerging but accelerating. The PEARL trial, published in Aging Cell in 2024, was a randomized, double-blind, placebo-controlled study of low-dose rapamycin in older adults. The trial found that rapamycin was well-tolerated at doses of 0.5 mg/day or 5 mg/week over 12 months, with no serious adverse events attributable to the drug [3]. Participants showed trends toward improved immune function and favorable shifts in aging biomarkers, though the trial was not powered to detect lifespan extension.

Dr. Jonathan An, lead author of the PEARL study, noted: "These results support the safety of low-dose rapamycin in healthy older adults and provide the foundation for larger, longer trials examining clinical endpoints" [3].

The FDA label for sirolimus lists the approved dose range for transplant rejection prophylaxis as a 6 mg loading dose followed by 2 mg/day maintenance [4]. The off-label longevity protocol uses substantially lower exposure: 3 to 6 mg once weekly, producing intermittent mTOR inhibition rather than the continuous suppression seen in transplant patients. This pulsed dosing pattern is thought to preferentially inhibit mTORC1 while sparing mTORC2, a distinction that may explain the more favorable side-effect profile observed in longevity patients compared to transplant populations [9].

Side Effects and Monitoring at Longevity Doses

The side-effect profile of once-weekly rapamycin at 3 to 6 mg differs meaningfully from the daily transplant-dose regimen. Common effects at longevity doses include mild mouth sores (aphthous ulcers) in approximately 15 to 25% of patients, transient elevations in LDL cholesterol, and occasional mild GI symptoms [3].

Serious immunosuppression, the primary concern with daily transplant dosing, has not been observed in published longevity-dose trials. The PEARL trial reported no increase in infections or hospitalizations in the rapamycin group compared to placebo over 12 months [3]. Still, prescribers in Georgia and elsewhere appropriately screen for latent infections (tuberculosis, hepatitis B) before initiation and counsel patients to report any signs of infection promptly.

Mouth sores, when they occur, typically resolve within 1 to 2 weeks and can be managed with topical corticosteroid rinses. If LDL rises more than 30% above baseline, most clinicians will add or adjust lipid-lowering therapy rather than discontinue rapamycin [10].

Monitoring visits at 4 to 6 weeks, 3 months, and 6 months after initiation are standard practice. These visits can be conducted via telehealth, with lab draws completed at a local Georgia facility. The prescriber reviews CBC, CMP, and fasting lipids at each monitoring interval and adjusts dosing if needed.

Sirolimus has a long half-life of approximately 62 hours, meaning that once-weekly dosing produces a peak-and-trough pharmacokinetic pattern [4]. Trough levels are not routinely measured in longevity patients the way they are in transplant recipients, but some clinicians order a trough level at the 6-week mark to confirm the patient is in the expected low-exposure range (typically <5 ng/mL for weekly dosing).